

Thierry AndrÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4839081/publications.pdf>

Version: 2024-02-01

296
papers

32,794
citations

21215

62
h-index

4853

174
g-index

328
all docs

328
docs citations

328
times ranked

25236
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
2	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	3.0	5
3	Immune checkpoint inhibitors in colorectal cancer: dream and reality. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 4-6.	3.7	2
4	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
5	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification. <i>Cancer Treatment Reviews</i> , 2022, 103, 102325.	3.4	26
6	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective EpiTopes-HPV01 and EpiTopes-HPV02 studies. <i>European Journal of Cancer</i> , 2022, 162, 138-147.	1.3	4
7	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
8	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 244-244.	0.8	39
9	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	0.8	12
10	Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 201-201.	0.8	5
11	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
12	Immune microenvironment in patients with mismatch repair proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. <i>Molecular Oncology</i> , 2022, 16, 2260-2273.	2.1	5
13	Reply to A. Smith et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200246.	0.8	0
14	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
15	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
16	Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 233-241.	1.8	18
17	Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy –“ Authors’ reply. <i>Lancet Oncology</i> , The, 2022, 23, e246.	5.1	1
18	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3606-3606.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Comparative analysis of microsatellite instability-high (MSI-H) <i>BRAF</i> V600E-mutated versus MSI-H <i>BRAF</i> wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3066-3066.	0.8	0
20	STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3504-3504.	0.8	6
21	Impact of <i>RAS</i> mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3067-3067.	0.8	2
22	Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2587-2587.	0.8	6
23	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3578-3578.	0.8	0
24	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
25	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 208-211.	3.0	56
26	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	3.0	5
27	Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 9-16.	1.3	40
28	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	1.0	4
29	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	3.0	44
30	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9-9.	0.8	69
31	KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6-6.	0.8	39
32	Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer. , 2021, 9, e001903.		15
33	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84
34	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
35	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
36	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. <i>Cancers</i> , 2021, 13, 1149.	1.7	30

#	ARTICLE	IF	CITATIONS
37	Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessity. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100058.	3.0	0
38	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	5.1	110
39	Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2564-2564.	0.8	25
40	Prevalence of <i>NTRK1/3</i> fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15537-e15537.	0.8	2
41	Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3580-3580.	0.8	1
42	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
43	Letter to the Editor from Colle et al. , 2021, 9, e002997.		1
44	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5638-5646.	3.2	42
45	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021, 15, 2401-2411.	2.1	11
46	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
47	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021, 161, 814-826.e7.	0.6	36
48	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	0.8	45
49	Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	0
50	Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , 2020, 110, 404-412.	1.2	12
51	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, 107-114.	0.4	24
52	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-19.	0.8	623
53	Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. <i>Annals of Surgical Oncology</i> , 2020, 27, 877-885.	0.7	7
54	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020, 124, 91-101.	1.3	68

#	ARTICLE	IF	CITATIONS
55	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65
56	Immune scores in colorectal cancer: Where are we?. European Journal of Cancer, 2020, 140, 105-118.	1.3	50
57	A new prognostic and predictive tool for shared decision making in stage III colon cancer. European Journal of Cancer, 2020, 138, 182-188.	1.3	27
58	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy—A Multicenter Study by the French Sarcoma Group. American Journal of Roentgenology, 2020, 215, 1539-1548.	1.0	21
59	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tff 50 Lancet Oncology, The, 2020, 21, 1620-1629.	5.1	152
60	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 2020, 383, 2207-2218.	13.9	1,513
61	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers, 2020, 12, 1990.	1.7	12
62	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 2350.	1.7	30
63	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097535.	1.4	24
64	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
65	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. JAMA Network Open, 2020, 3, e2020425.	2.8	11
66	Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial. Digestive and Liver Disease, 2020, 52, 730-733.	0.4	18
67	A comprehensive overview of promising biomarkers in stage II colorectal cancer. Cancer Treatment Reviews, 2020, 88, 102059.	3.4	12
68	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Journal of Clinical Oncology, 2020, 38, 1702-1710.	0.8	40
69	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	3.2	39
70	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Annals of Oncology, 2020, 31, 246-256.	0.6	20
71	First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. Future Oncology, 2020, 16, 21-29.	1.1	20
72	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. International Journal of Cancer, 2020, 147, 285-296.	2.3	56

#	ARTICLE	IF	CITATIONS
73	A Correlative Study of Sunflower Seed Vigor Components as Related to Genetic Background. <i>Plants</i> , 2020, 9, 386.	1.6	9
74	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
75	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
76	Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMO3 DREAM Phase III Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 200-208.e1.	1.0	7
77	Para-aortic lymph node metastasis detected intraoperatively by systematic frozen section examination in pancreatic head adenocarcinoma: is resection improving the prognosis?. <i>Hpb</i> , 2020, 22, 1604-1612.	0.1	9
78	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
79	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4004-4004.	0.8	28
80	A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4010-4010.	0.8	8
81	Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4032-4032.	0.8	10
82	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA4-LBA4.	0.8	150
83	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 218-218.	0.8	5
84	A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS266-TPS266.	0.8	14
85	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4099-4099.	0.8	1
86	Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15114-e15114.	0.8	0
87	Pazopanib or methotrexate+vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
88	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , 2019, 121, 312-317.	2.9	17
89	Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma. <i>Case Reports in Gastrointestinal Medicine</i> , 2019, 2019, 1-3.	0.2	0
90	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1153-1161.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms. Digestive and Liver Disease, 2019, 51, 1198-1201.	0.4	1
92	Is it permissible to undertake surgery for adrenal metastases of esophageal adenocarcinomas?. Journal of Visceral Surgery, 2019, 156, 275.	0.4	2
93	Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Clinical Colorectal Cancer, 2019, 18, 200-208.e1.	1.0	12
94	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. European Journal of Cancer, 2019, 112, 12-19.	1.3	8
95	Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. International Journal of Oncology, 2019, 54, 1433-1445.	1.4	7
96	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. British Journal of Cancer, 2019, 120, 697-702.	2.9	19
97	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treatment Reviews, 2019, 75, 1-11.	3.4	53
98	RECIST and Choi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. Cancer Imaging, 2019, 19, 85.	1.2	9
99	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	1.9	89
100	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncology, 2019, 5, 551.	3.4	178
101	Receptivity to Freestream Acoustic Noise in Hypersonic Flow over a Generic Forebody. Journal of Spacecraft and Rockets, 2019, 56, 447-457.	1.3	4
102	Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. Clinical Rheumatology, 2019, 38, 601-602.	1.0	17
103	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tumor. JAMA Oncology, 2019, 5, 551.	1.0	17
104	Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Bulletin Du Cancer, 2019, 106, 137-142.	0.6	22
105	Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. Surgical Oncology, 2019, 28, 121-127.	0.8	12
106	Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. Journal of Clinical Oncology, 2019, 37, 3121-3121.	0.8	1
107	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.. Journal of Clinical Oncology, 2019, 37, 3502-3502.	0.8	5
108	Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the) Tumor. JAMA Oncology, 2019, 5, 551.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2019, 37, 3513-3513.	0.8	8
110	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.. Journal of Clinical Oncology, 2019, 37, 3525-3525.	0.8	1
111	Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.. Journal of Clinical Oncology, 2019, 37, 3547-3547.	0.8	1
112	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	0.8	31
113	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. Journal of Clinical Oncology, 2019, 37, e15046-e15046.	0.8	0
114	Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2019, 37, 3519-3519.	0.8	0
115	Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms. Neuroendocrinology, 2018, 107, 24-31.	1.2	41
116	Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of <i>RAS</i> Status. Clinical Cancer Research, 2018, 24, 2548-2558.	3.2	14
117	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> ^{V600E} -Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	7.7	448
118	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and Liver Disease, 2018, 50, 305-307.	0.4	13
119	Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Gastroenterology, 2018, 154, 1061-1065.	0.6	79
120	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	13.9	699
121	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clinical Colorectal Cancer, 2018, 17, 170-178.e3.	1.0	41
122	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Journal of the National Cancer Institute, 2018, 110, 68-77.	3.0	89
123	Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. Journal of Clinical Oncology, 2018, 36, 1469-1477.	0.8	122
124	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	0.8	1,525
125	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. Journal of Gastrointestinal Oncology, 2018, 9, E23-E27.	0.6	7
126	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29

#	ARTICLE	IF	CITATIONS
127	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
128	Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 3271-3279.	0.7	38
129	Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments. <i>European Journal of Cancer</i> , 2018, 97, 55-56.	1.3	5
130	Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 277-300.	2.3	15
131	DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11501-11501.	0.8	7
132	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3599-3599.	0.8	6
133	Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3603-3603.	0.8	4
134	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-554.	0.8	39
135	Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 737-737.	0.8	3
136	Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 816-816.	0.8	3
137	FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 817-817.	0.8	2
138	KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS877-TPS877.	0.8	31
139	FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 110-118.	0.9	9
140	Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 724-724.	0.8	0
141	Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-728.	0.8	14
142	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3568-3568.	0.8	0
143	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQq1 1 0.784314 rgBT /Over TPS3622-TPS3622.	0.8	0
144	Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3601-3601.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2017, 49, 359-367.	0.4	65
146	Immunotherapy and patients treated for cancer with microsatellite instability. <i>Bulletin Du Cancer</i> , 2017, 104, 42-51.	0.6	64
147	MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 192-201.	5.1	138
148	Mutational signature analysis identifies <i>MUTYH</i> deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130
149	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 9.	1.3	51
150	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 337-346.	3.7	28
151	Genetic control of plasticity of oil yield for combined abiotic stresses using a joint approach of crop modelling and genome-wide association. <i>Plant, Cell and Environment</i> , 2017, 40, 2276-2291.	2.8	66
152	Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers": <i>Current Treatment Options in Oncology</i> , 2017, 18, 63.	1.3	0
153	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. <i>European Journal of Cancer</i> , 2017, 86, 266-274.	1.3	65
154	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
155	Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval. <i>Digestive and Liver Disease</i> , 2017, 49, 924-928.	0.4	6
156	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <i>Colorectal Cancer</i> , 2017, 6, 23-31.	0.8	1
157	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
158	Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). <i>Clinical Colorectal Cancer</i> , 2017, 16, 129-140.e4.	1.0	12
159	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). <i>BMC Cancer</i> , 2017, 17, 574.	1.1	22
160	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3071-3071.	0.8	107
161	Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3500-3500.	0.8	5
162	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3520-3520.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3531-3531.	0.8	26
164	Effect of postoperative morbidity on survival after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis in a series of 700 cases.. Journal of Clinical Oncology, 2017, 35, 3565-3565.	0.8	1
165	A phase IIb of eraspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).. Journal of Clinical Oncology, 2017, 35, e15718-e15718.	0.8	3
166	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology, 2017, 35, LBA1-LBA1.	0.8	17
167	Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.. Journal of Clinical Oncology, 2017, 35, TPS3618-TPS3618.	0.8	1
168	A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, TPS3626-TPS3626.	0.8	2
169	CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS4131-TPS4131.	0.8	3
170	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology, 2017, 35, LBA1-LBA1.	0.8	31
171	Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. Journal of Clinical Oncology, 2017, 35, 350-350.	0.8	2
172	KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS815-TPS815.	0.8	22
173	Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.. Journal of Clinical Oncology, 2017, 35, 300-300.	0.8	1
174	Positive effect on survival of epidural analgesia in patients undergoing cytoreductive surgery for peritoneal metastasis.. Journal of Clinical Oncology, 2017, 35, e15064-e15064.	0.8	0
175	Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.. Journal of Clinical Oncology, 2017, 35, 3563-3563.	0.8	0
176	MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PTO26).. Journal of Clinical Oncology, 2017, 35, 3530-3530.	0.8	0
177	Abstract 2734: Impact of circulating and tissue biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II Study. , 2017, , .		0
178	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer, 2016, 16, 412.	1.1	89
179	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
180	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	0.5	9

#	ARTICLE	IF	CITATIONS
181	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	1.3	5
182	<sc>PEPCOL</sc>: a <sc>GERCOR</sc> randomized phase <sc>II</sc> study of nanoliposomal irinotecan <sc>PEP</sc>02 (<sc>MM</sc>398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. <i>Cancer Medicine</i> , 2016, 5, 676-683.	1.3	44
183	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3711-3712.	0.8	6
184	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , 2016, 115, 281-289.	2.9	61
185	Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. <i>Acta Oncologica</i> , 2016, 55, 1168-1174.	0.8	18
186	<i>HSP110</i>T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 377-384.	1.5	46
187	New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2016, 18, 18.	1.8	12
188	Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 250-256.	1.0	12
189	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	0.8	32
190	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 843-853.	0.8	128
191	PRODIGE 34 "FFCD 1402" ADAGE. <i>Digestive and Liver Disease</i> , 2016, 48, 206-207.	0.4	26
192	Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 863-869.	0.7	42
193	Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3501-3501.	0.8	90
194	KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3631-TPS3631.	0.8	4
195	Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).. <i>Journal of Clinical Oncology</i> , 2016, 34, 274-274.	0.8	2
196	The prospective French participation to IDEA (International Duration Evaluation of Adjuvant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 6 months of adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 633-633.	0.8	2
197	KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS787-TPS787.	0.8	12
198	Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. <i>PLoS ONE</i> , 2016, 11, e0157067.	1.1	17

#	ARTICLE	IF	CITATIONS
199	KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS789-TPS789.	0.8	4
200	The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.. Journal of Clinical Oncology, 2016, 34, 2073-2073.	0.8	0
201	A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).. Journal of Clinical Oncology, 2016, 34, 3537-3537.	0.8	7
202	Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.. Journal of Clinical Oncology, 2016, 34, 3553-3553.	0.8	0
203	Peritoneal mesothelioma: Evaluation of chemotherapeutic agents used for HIPEC through the RENAPE database.. Journal of Clinical Oncology, 2016, 34, 4101-4101.	0.8	0
204	Curative treatment for patients with synchronous liver metastases and peritoneal carcinomatosis of advanced colorectal cancer (aCRC): A multicenter study of the French Association of Surgery.. Journal of Clinical Oncology, 2016, 34, 3558-3558.	0.8	1
205	KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS3639-TPS3639.	0.8	0
206	Impact of OPTIMOX-afibercept as first-line therapy on time to health-related quality of life deterioration in patients with unresectable metastatic colorectal cancer: results of the GERCOR VELVET phase II single arm study.. Journal of Clinical Oncology, 2016, 34, e15009-e15009.	0.8	0
207	Multimodal treatment choice and feasibility in older patients with resectable gastric cancer: a multicentric cohort study.. Journal of Clinical Oncology, 2016, 34, e15528-e15528.	0.8	0
208	Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.. Journal of Clinical Oncology, 2016, 34, 3620-3620.	0.8	0
209	Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation. , 2016, , .		0
210	Global Mode Analysis in the L/T Transition of a Hypersonic Boundary Layer Forced by Wall Injection. Procedia IUTAM, 2015, 14, 58-67.	1.2	1
211	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer, 2015, 15, 653.	1.1	9
212	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Pancreas, 2015, 44, 1141-1147.	0.5	64
213	Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Therapeutic Advances in Medical Oncology, 2015, 7, 153-169.	1.4	50
214	Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clinical Therapeutics, 2015, 37, 1301-1316.	1.1	26
215	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. Bulletin Du Cancer, 2015, 102, 324-331.	0.6	47
216	Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma. Clinical Cancer Research, 2015, 21, 1215-1224.	3.2	63

#	ARTICLE	IF	CITATIONS
217	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4176-4187.	0.8	515
218	Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1493-1505.	5.1	106
219	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 496.	1.1	20
220	Analysis of <i>KRAS</i> / <i>NRAS</i> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5469-5479.	3.2	152
221	Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 103-103.	0.8	43
222	Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcS@ Program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2595-2595.	0.8	11
223	Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3593-3593.	0.8	1
224	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3632-TPS3632.	0.8	3
225	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 235-235.	0.8	1
226	Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2â€”Results of the induction phase of the GERCOR DREAM randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 670-670.	0.8	4
227	PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancerâ€”A GERCOR Study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 751-751.	0.8	1
228	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. <i>PLoS ONE</i> , 2015, 10, e0135907.	1.1	16
229	FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3567-3567.	0.8	0
230	Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6580-6580.	0.8	0
231	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	62
232	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with <i>KRAS</i> Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3338-3347.	3.2	98
233	Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 329-338.	1.0	0
234	Prognostic Impact of Deficient DNA Mismatch Repair and <i>KRAS</i> and BRAF V600E Mutations in Patients with Lymph-Node-Positive Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 346-353.	1.0	11

#	ARTICLE	IF	CITATIONS
235	Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (FÂ©dÂ©ration Francophone de CancÂ©rologie Digestive, FÂ©dÂ©ration Nationale des Centres de Tj BTQq1 120784314 <i>Clinical Oncology, 2014, 32, 3500-3506.</i>	0.8	53
236	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology, 2014, 32, 3507-3507.</i>	0.8	1
237	Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).. <i>Journal of Clinical Oncology, 2014, 32, 3601-3601.</i>	0.8	1
238	Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer. <i>Current Colorectal Cancer Reports, 2013, 9, 278-285.</i>	1.0	1
239	Platinum-sensitivity in metastatic colorectal cancer: Towards a definition. <i>European Journal of Cancer, 2013, 49, 3813-3820.</i>	1.3	41
240	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Â©months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports, 2013, 9, 261-269.</i>	1.0	94
241	Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer. <i>Clinical Cancer Research, 2013, 19, 1902-1912.</i>	3.2	214
242	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. <i>Lancet Oncology, The, 2013, 14, 29-37.</i>	5.1	997
243	Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer. <i>Current Colorectal Cancer Reports, 2013, 9, 292-301.</i>	1.0	2
244	Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. <i>Journal of Chemotherapy, 2013, 25, 104-111.</i>	0.7	7
245	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. <i>Journal of Clinical Oncology, 2013, 31, 3656-3663.</i>	0.8	65
246	Reply to M. GallÂ©n et al and R.S. Midgley et al. <i>Journal of Clinical Oncology, 2013, 31, 1611-1612.</i>	0.8	3
247	Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age. <i>Colorectal Cancer, 2013, 2, 205-217.</i>	0.8	0
248	Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial. <i>Journal of Clinical Oncology, 2012, 30, 3353-3360.</i>	0.8	330
249	Therapeutic strategy in unresectable metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology, 2012, 4, 75-89.</i>	1.4	73
250	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The, 2012, 13, 1225-1233.</i>	5.1	484
251	Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies. <i>Clinical Colorectal Cancer, 2012, 11, 127-137.</i>	1.0	22
252	Analysis of neurosensory adverse events induced by FOLFOX 4 treatment in colorectal cancer patients: a comparison between two A sian studies and four W estern studies. <i>Cancer Medicine, 2012, 1, 198-206.</i>	1.3	10

#	ARTICLE	IF	CITATIONS
253	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2012, 143, 664-674.e6.	0.6	218
254	Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 223-230.	1.8	0
255	Final results of study 20050181: A randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the secondâ€line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3535-3535.	0.8	1
256	Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA3500-LBA3500.	0.8	18
257	DPD deficiency: Medicoeconomic evaluation of pretreatment screening of 5-FU toxicity.. <i>Journal of Clinical Oncology</i> , 2012, 30, 410-410.	0.8	5
258	Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA3500-LBA3500.	0.8	0
259	The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 218-226.	1.0	24
260	From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer. <i>Seminars in Oncology</i> , 2011, 38, 521-532.	0.8	40
261	Simplified Prognostic Model in Patients with Oxaliplatinâ€Based or Irinotecanâ€Based Firstâ€Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study. <i>Oncologist</i> , 2011, 16, 1228-1238.	1.9	73
262	Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 148-157.	1.0	2
263	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4706-4713.	0.8	909
264	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	0.8	67
265	Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. <i>Clinical Colorectal Cancer</i> , 2010, 9, 269-273.	1.0	7
266	Stage II and Stage III Colon Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 202-209.	1.0	39
267	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	0.8	539
268	Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3109-3116.	0.8	1,935
269	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	0.8	437
270	Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 166-170.	1.0	1

#	ARTICLE	IF	CITATIONS
271	Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5727-5733.	0.8	348
272	<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 374-379.	0.8	1,398
273	Concomitant Administration of Weekly Oxaliplatin, Fluorouracil Continuous Infusion, and Radiotherapy After 2 Months of Gemcitabine and Oxaliplatin Induction in Patients With Locally Advanced Pancreatic Cancer: A Groupe Coordinateur Multidisciplinaire en Oncologie Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1080-1085.	0.8	55
274	Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2008, 26, 2336-2341.	0.8	193
275	Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies. <i>Journal of Clinical Oncology</i> , 2007, 25, 326-331.	0.8	485
276	Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1. <i>Journal of Clinical Oncology</i> , 2007, 25, 3732-3738.	0.8	135
277	Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3224-3229.	0.8	121
278	FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer. <i>Cancer</i> , 2007, 110, 2666-2671.	2.0	81
279	Adjuvant Therapy for Stage II and III Colorectal Cancer. <i>Seminars in Oncology</i> , 2007, 34, S37-S40.	0.8	27
280	Cetuximab efficacy in patients treated routinely in university hospitals. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 941-949.	0.9	3
281	Current status of adjuvant therapy for colon cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 90-7.	0.8	12
282	Update on targeted agents for adjuvant treatment of colon cancer in 2006. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S47-9.	0.8	2
283	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. <i>Annals of Surgical Oncology</i> , 2006, 13, 887-898.	0.7	89
284	Targeted Agents for Adjuvant Therapy of Colon Cancer. <i>Seminars in Oncology</i> , 2006, 33, 42-45.	0.8	26
285	Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4085-4091.	0.8	443
286	OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 394-400.	0.8	750
287	Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: Induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms. <i>International Journal of Oncology</i> , 2005, 27, 553.	1.4	2
288	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607

#	ARTICLE	IF	CITATIONS
289	Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. <i>European Journal of Cancer</i> , 2005, 41, 2262-2267.	1.3	108
290	Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 645-650.	0.9	12
291	FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 229-237.	0.8	2,718
292	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2343-2351.	13.9	3,268
293	An Overview of Adjuvant Systemic Chemotherapy for Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, S22-S28.	1.0	38
294	Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 2896-2903.	0.8	256
295	Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 903-911.	0.4	58
296	Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen. <i>Journal of Clinical Oncology</i> , 1999, 17, 3560-3568.	0.8	259